Polycystic kidney disease: a 2011 update

被引:27
作者
Steinman, Theodore I. [1 ,2 ,3 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02215 USA
[3] Brigham & Womens Hosp, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
assessing progression in autosomal dominant polycystic kidney disease; autosomal dominant polycystic kidney disease; research initiatives in PKD; therapeutic trials in polycystic kidney disease in progress; LEFT-VENTRICULAR HYPERTROPHY; LONG-ACTING SOMATOSTATIN; VOLUME PROGRESSION; RENAL-FUNCTION; LIVER-DISEASE; RECTAL GLAND; SECRETION; ABNORMALITIES; TOLVAPTAN; CHILDREN;
D O I
10.1097/MNH.0b013e32835011a7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review The review will examine clinically relevant advances in the area of polycystic kidney disease (PKD), mainly focusing on autosomal dominant polycystic kidney disease (ADPKD). Discussion will focus on predicting the course of ADPKD, clinical trials and new research endeavors. Recent findings During the past several years PKD research has been one of the most prolific areas in investigative nephrology. Research endeavors have focused on decreasing cyst proliferation and cyst fluid formation based on an understanding of the pathophysiology of these processes. If cysts can be prevented from growing, kidney function can be better preserved. Summary Progression of this most common inherited kidney disorder can be altered by understanding that cysts are the disease in ADPKD. Assessing total kidney volume and noting its relationship to glomerular filtration rate is key in predicting the course of the disease and will aid in the evaluation of the new research initiatives that are designed to stop cyst proliferation and fluid secretion into the kidney cysts. The role of biomarkers is an advancement in predicting PKD progression and can potentially be used in evaluation of treatments for this disease. Complications of PKD alter the course and prognosis; hence management approaches will be addressed.
引用
收藏
页码:189 / 194
页数:6
相关论文
共 43 条
[1]  
[Anonymous], B MT DESERT ISL BIOL
[2]   A Pilot Clinical Study to Evaluate Changes in Urine Osmolality and Urine cAMP in Response to Acute and Chronic Water Loading in Autosomal Dominant Polycystic Kidney Disease [J].
Barash, Irina ;
Ponda, Manish P. ;
Goldfarb, David S. ;
Skolnik, Edward Y. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (04) :693-697
[3]  
Chapman AB, 1997, J AM SOC NEPHROL, V8, P1292
[4]  
EPSTEIN FH, 1983, J EXP BIOL, V106, P25
[5]   Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: A longitudinal study [J].
Fick-Brosnahan, GM ;
Belz, MM ;
McFann, KK ;
Johnson, AM ;
Schrier, RW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (06) :1127-1134
[6]   AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY-DISEASE [J].
GABOW, PA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (05) :332-342
[7]   Autosomal dominant polycystic kidney disease [J].
Grantham, Jared J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (14) :1477-1485
[8]   Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes [J].
Grantham, Jared J. ;
Chapman, Arlene B. ;
Torres, Vicente E. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (01) :148-157
[9]   Volume progression in polycystic kidney disease [J].
Grantham, JJ ;
Torres, VE ;
Chapman, AB ;
Guay-Woodford, LM ;
Bae, KT ;
King, BF ;
Wetzel, LH ;
Baumgarten, DA ;
Kenney, PJ ;
Harris, PC ;
Klahr, S ;
Bennett, WM ;
Hirschman, GN ;
Meyers, CM ;
Zhang, XL ;
Zhu, F ;
Miller, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (20) :2122-2130
[10]   Comparison of phenotypes of polycystic kidney disease types 1 and 2 [J].
Hateboer, N ;
Dijk, MAV ;
Bogdanova, N ;
Coto, E ;
Saggar-Malik, AK ;
San Millan, JL ;
Torra, R ;
Breuning, M ;
Ravine, D .
LANCET, 1999, 353 (9147) :103-107